Trial Profile
A Placebo-controlled, Cross-over, Study to Assess the Efficacy of the Oral Mast Cell Inhibitor Pemirolast in Allergen-induced Airway Obstruction and Inflammation in Subjects With Allergic Asthma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Pemirolast (Primary)
- Indications Allergic asthma
- Focus Therapeutic Use
- Acronyms PEMAG
- 06 May 2019 Status changed from recruiting to discontinued.
- 21 Apr 2017 New trial record